Universitair Ziekenhuis Gent
Universitair Ziekenhuis Gent is recorded as a service provider in 12 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 12 of 12 trials · Latest update first
A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ‑73763989 + Nucleos(t)ide Analog in Participants Co‑infected with Hepatitis B and Hepatitis D Virus
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- Approximately 50% of the first 22 Part 1 participants experienced on-treatment ALT elevations, and protocol management criteria were amended because some elevations were prolonged.
- New enrollment was temporarily halted in December 2022 after significant ALT elevations were observed more frequently in Part 2 participants with screening or baseline HBsAg >10,000 IU/mL.
- Enrollment was not reopened because the sponsor discontinued further investment in its hepatitis B and D discovery and development programs.
- Part 2 open-label treatment was reduced to Week 96 and follow-up to 24 weeks under protocol amendment 5.
- Sustained HBV response was not collected or analyzed because follow-up was shortened and participants continued NA treatment during follow-up.
These findings describe the trial, not the service provider’s performance or responsibility.
A Two-Part Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK-7480 in Healthy Participants
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available1 trial-level finding · Read insights
- Amendment 03 added Panel D to evaluate safety, tolerability, and pharmacokinetics at higher MK-7480 doses in light of emerging pharmacokinetic data.
These findings describe the trial, not the service provider’s performance or responsibility.
A Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK-3508 in Healthy Participants
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available4 trial-level findings · Read insights
- Amendments added two panels to explore higher MK-3508 doses.
- Planned doses were revised downward based on emerging pharmacokinetic data.
- An amendment added inclusion-criteria requirements and an additional stopping criterion.
- An amendment clarified concomitant-medication restrictions and study procedures and added safety monitoring.
These findings describe the trial, not the service provider’s performance or responsibility.
LBL 2018 – International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma
Sponsor Universitaetsklinikum Muenster AöR
- Start (EU)
- Latest update
- Estimated end
Phase 1/2, first-in-human, randomized, double-blind, reference-controlled study to evaluate the safety and immunogenicity of an extemporaneously mixed Combo Inactivated Influenza Vaccine (Green Cross [GC]-IIV; 15µg of each hemagglutinin [HA])/OVX836 (480µg), in comparison to GC-IIV (15µg of each HA) concomitantly administered with OVX836 (480µg), GC-IIV alone (15 µg each HA), OVX836 alone (480µg), and a licensed reference trivalent IIV (Vaxigrip®; 15µg of each HA), administered intramuscularly (IM) in healthy participants
Sponsor Osivax
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Perioperative zanidatamab combined with chemotherapy in HER2-positive locally advanced operable gastroesophageal adenocarcinoma (GEA): a Phase 1b/2a single-arm trial
Sponsor UZ Leuven
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Participants living with Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A randomized controlled non-inferiority trial comparing 7 versus 14 days of ciprofloxacin for male urinary tract infections with systemic involvement.
Sponsor UZ Brussel
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-7602 in Healthy Participants
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Single Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1403 in Healthy Male Participants
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase 2a, single center, randomized, double-blind, study to evaluate the immunogenicity and safety of one single administration of OVX836 influenza vaccine at two dose levels (180µg or 480μg) given intramuscularly (IM), either as a booster or a primary vaccination in healthy adults previously administered with OVX836, Influvac Tetra® or placebo in the OVX836-002 (EudraCT number: 2019-002939-28) and OVX836-003 (EudraCT number: 2021-002535-39) studies
Sponsor OSIVAX Belgique
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase II RAINSPOT: a multicentric open label trial of Zolbetuximab-Paclitaxel-Ramucirumab in second line setting for CLDN18.2 positive gastro-esophageal adenocarcinoma
Sponsor UZ Leuven
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Universitair Ziekenhuis Gent?
The 2026-10-09 snapshot links Universitair Ziekenhuis Gent to 12 distinct CTIS trials. Recorded services include Laboratory services, Medicinal product management, Relabeling and distribution IMP, Clinical monitoring, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Universitair Ziekenhuis Gent?
The most frequently recorded therapeutic areas are Gastroenterology, Hepatology, Infectious Disease, Haematological Malignancies. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Universitair Ziekenhuis Gent conducted?
The linked trials record locations in 15 countries, including Belgium, Italy, Spain, France, Sweden. These are trial locations, not confirmed office locations or countries where Universitair Ziekenhuis Gent delivered services.
What can this page tell me about Universitair Ziekenhuis Gent's trial experience?
Browse 12 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 3 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Universitair Ziekenhuis Gent. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Universitair Ziekenhuis Gent